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S U M M A R Y
Objectives: To describe HIV RNA levels during tuberculosis (TB) infection in patients co-infected with TB
and HIV. Moreover, to examine the p24 antigen proﬁle during TB treatment.
Methods: We examined the changes in CD4 cell count, HIV RNA, and p24 levels during anti-tuberculous
therapy in a group of TB/HIV-1 co-infected and HIV-untreated patients from Guinea-Bissau.
Results: A total of 365 TB patients were enrolled, of whom 76 were co-infected with HIV-1 and 19 were
dually infected with HIV-1 + HIV-2. No signiﬁcant changes in CD4, HIV RNA, or p24 levels were found
during 8 months of TB treatment. HIV RNA levels correlated well with p24 (Spearman’s R2 = 0.52,
p < 0.00001) and both markers were strong predictors of mortality. Initial HIV RNA levels correlated
with a clinical TB severity index – the TBscore (Spearman’s R2 = 0.23, p = 0.02) – and the TBscore
decreased dramatically during TB treatment although HIV RNA levels remained unchanged.
Conclusion: We found no signiﬁcant changes in CD4, HIV RNA, or p24 antigen levels during 8 months of
TB treatment among TB/HIV co-infected individuals, who did not receive antiretroviral treatment. The
markers were unaffected by a strong improvement in TBscore and all three markers showed predictive
capacity for mortality risk.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Tuberculosis (TB) and the human immunodeﬁciency virus
(HIV) are among the world’s most severe public health threats.
We have previously shown that 35% of TB patients in Guinea-
Bissau are co-infected with HIV;1 in South Africa the percentage
is estimated to be >60%.2 The progression of HIV seems to be
accelerated by Mycobacterium tuberculosis co-infection3,4, and
active TB has been associated with marked increases in HIV RNA
levels.3 Yet, reports on HIV RNA levels during M. tuberculosis
(MTB) infection vary. Goletti et al.3 found increased levels at the
time of MTB diagnosis among HIV-infected patients receiving no
antiretroviral treatment (ART), with lower levels prior to
infection as well as after anti-mycobacterial treatment. Like-
wise, a study from the UK found signiﬁcant decreases in viral
load after treatment of TB irrespective of concurrent ART
treatment. Though patients receiving dual therapy had more* Corresponding author.
E-mail addresses: wejse@dadlnet.dk, wejse@skejby.rm.dk (C. Wejse).
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also had substantial declines: from 4.91 log HIV RNA at TB
diagnosis to 3.97 log HIV RNA at month 12.5 However, studies
from developing countries have not been able to reproduce these
ﬁndings. Studies from Coˆte d’Ivoire, South Africa, and Ghana
have shown either no change6,7 or increasing viral loads during
anti-TB treatment. A study from Uganda found an increase in
viral load among patients with low HIV RNA at baseline and a
decrease among patients with high viral load at baseline.8
Interestingly, various inﬂammation markers, i.e., sTNF-a, b-2
microglobulin, and neopterin,6 as well as interleukin 6 (IL-6),7,9
have been shown to decrease signiﬁcantly during anti-TB
treatment, but in none of these studies were the changes
paralleled by changes in viral load or CD4 cell count.
The HIV-1 antigen p24 has been proposed as an alternative
marker of HIV progression. p24 has been shown to correlate well
with HIV RNA and to have a prognostic value.10 However, only a
few studies have examined the prognostic capabilities of p24
measurements. Furthermore, the p24 antigen proﬁle during TB
treatment of HIV co-infected patients not receiving ART has not
previously been analyzed.ses. Published by Elsevier Ltd. All rights reserved.
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HIV-1/TB co-infected patients treated for TB but not receiving
ART.5 There are several reports indicating that the CD4 count is low
in active TB, even in the HIV-uninfected,11–13 but it was only
reported recently that CD4 counts in the HIV-uninfected were
unaffected by anti-tuberculous therapy.14
This study reports changes in CD4 cell count, HIV RNA, and p24
levels during anti-tuberculous therapy lasting 8 months in a group
of TB/HIV-1 co-infected patients from Guinea-Bissau.
2. Methods
The study site was the Bandim Health Project, a Health and
Disease Surveillance Site (HDSS) located in Guinea-Bissau, West
Africa, a member of the INDEPTH network of HDSS. Guinea-Bissau
has a poor, urban population of 102 000, with a high TB incidence
(470/100 000).15
2.1. Study design
We used the framework of a randomized trial of vitamin D
supplementation for TB patients, the TBVD trial,1 for the study of
CD4 count, HIV RNA, and p24 levels among HIV-1/TB co-infected
patients. Inclusion criteria were a diagnosis of TB either by sputum
examination (smear microscopy, no culture was available) or by
the World Health Organization (WHO) clinical criteria,16,17 age
15 years, and residence in the study area. There were no
exclusion criteria. None of the HIV-infected patients received ART,
which was not available in Guinea-Bissau at the time. All patients
received anti-tuberculous treatment consisting of 2 months of
daily observed treatment (DOT) with ethambutol (E), isoniazid (H),
rifampin (R), and pyrazinamide (Z), followed by 6 months of H+E.
2.2. Follow-up
Patients were invited to clinical follow-up examinations after 2,
5, and 8 months of treatment, and a household visit after 1 year,
until death or until moving out of the study area. Verbal autopsies
were conducted on all deaths; a physician used a standardized
questionnaire to obtain information from the closest relative. No
traumatic deaths were recorded; all died of causes that could be
related to TB or HIV.
2.3. Measurements
The severity of TB was assessed by TBscore, recording signs,
symptoms, and anthropometry: cough, chest pain, hemoptysis,
dyspnea, night sweating, anemia, tachycardia, lung auscultation
ﬁndings, fever, body mass index, and mid upper arm circumfer-
ence, with a maximal score of 13. The TBscore has been validated in
another cohort and has been grouped into severity classes as
follows: I, 0–5 points; II, 6–7 points; and III, 8 points.18
Blood samples were analyzed for HIV at the National Public
Health Laboratory in Guinea-Bissau. Sera were screened using
Enzygnost Anti-HIV 1/2 Plus (Behring Diagnostics GmbH, Marburg,
Germany) and reactive sera were conﬁrmed with Capillus HIV-1/
HIV-2 (Cambridge Diagnostics, Galway, Ireland), as well as
ImmunoComb II HIV-1&2 Bispot (Orgenics, Yavne, Israel).
T-lymphocyte subsets were determined at the National Public
Health Laboratory, Guinea-Bissau, by ﬂow cytometry (FACStrak;
Becton Dickinson, San Jose, CA, USA) with the use of three two-
color immunoﬂuorescence reagents, CD45/CD14, CD3/CD4, and
CD3/CD8 (Simultest, Becton Dickinson, San Jose, CA, USA).
Leukocyte and differential counts were performed manually.
HIV RNA and p24 antigen analyses were performed at the AIDS
Laboratory at Rigshospitalet, Copenhagen, Denmark. For the HIV-1RNA quantiﬁcation, 100 ml of plasma was suspended in 900 ml
phosphate buffered saline (PBS) and the samples were analyzed by
COBAS AmpliPrep/COBAS Taqman 48 HIV-1 Test v1.0 and v2.0
(Roche diagnostics, GmbH, Mannheim, Germany), in accordance
with the manufacturer’s instructions. Due to the reduction in input
volume (100 ml vs. 1000 ml routinely used), the lower limit of
detection (LLD) was set at 400 copies/ml in v1.0 and 200 copies/ml
in v2.0. Due to a higher than expected proportion of patients with
an undetectable viral load using v1.0, we chose to re-analyze with
v2.0 once this method became available.
p24 was performed using the PerkinElmer p24 Ultrasensitive
Assay Protocol (PerkinElmer, Life Sciences, Inc., Boston, MA, USA),
in accordance with the manufacturer’s instruction, except for the
use of the virus disruption buffer as described by Schu¨pbach et al.19
According to the manufacturer’s instructions, the lower level of
detection is run-speciﬁc.
2.4. Statistical analyses
p24 and HIV RNA measurements were log-transformed to
approximate normal distribution. We expressed variables by
their means or medians and standard deviations or range.
Pearson’s Chi-square test was used to assess statistical differ-
ences in proportions between groups, Student’s t-test to assess
differences in means between two groups when normal
distribution was present, and the Wilcoxon rank-sum test was
used when non-parametric analysis was needed. Linear and
logistic regression analyses were used as multivariate models to
adjust clinical outcomes for other factors. Cox regression and the
Wilcoxon–Breslow–Gehan log rank test for equality of survivor
functions were used to analyze mortality, and Kaplan–Meier
survival graphs were used to estimate the survival function. A
two-sided p-value of < 0.05 was considered signiﬁcant. Statisti-
cal analyses were performed with STATA version 9 software
(StataCorp, TX, USA).
3. Results
Recruitment began in November 2003 and ended in December
2005. Follow-up was completed in December 2006. A total of 365
TB patients were enrolled; 76 were co-infected with HIV-1 and 19
were dually infected with HIV-1 + HIV-2. Of these 95 patients, 93
(54 men and 39 women) had samples available for HIV RNA and
p24 measurement. Among these, 47 were alive and had samples
available at 8 months of follow-up. Due to technical problems on
several occasions, CD4+ T-lymphocyte counts were only available
for 276 patients at inclusion and for 187 patients at 8 months. The
baseline characteristics of the enrolled patients are shown in
Table 1.
3.1. Changes in CD4 in HIV-infected and HIV-uninfected TB patients
We found minor changes in CD4 count during TB treatment,
with a trend towards a higher CD4 count at the end of treatment
both for HIV-infected and for HIV-uninfected patients (Table 2).
The mean CD4 count at inclusion for the entire group of patients is
displayed in Table 1. At 8 months the mean CD4 counts was 675
cells/ml for the 120 HIV uninfected, and 306 cells/ml for the 35 HIV-
1 infected. For the 21 HIV-2 infected it was 327 cells/ml.
Table 2 displays the subgroup of HIV-uninfected patients with
both a baseline and a follow-up sample at 8 months.
3.2. Changes in HIV markers over time
Using v2.0 more virus was detected, hence fewer patients had
undetectable HIV RNA and more patients had high viral loads
Table 1
Baseline characteristics of TB patients
All patients
(n = 365)
HIV-1-infected
(n = 95a)
HIV-2-infected
(n = 57a)
HIV-uninfected
(n = 228)
Age, years, mean (SD) 37 (14) 37 (10) 40 (11) 37 (15)
Men, n (%) 222 (61) 54 (58) 28 (49) 143 (63)
Smear-positive, n (%) 247 (68) 60 (65) 35 (61) 160 (70)
HIV distribution, n (%)
HIV-1 76 (21) 76 (80) - -
HIV-2 36 (10) - 36 (65) -
HIV-1 + HIV-2 19 (5) 19 (20) 19 (35) -
HIV-negative 228 (62) - - 228
Missing 6 (2) - - -
CD4+ T-lymphocyte count, cells/ml, mean (range) 532 (6–2328) 307 (6–1531) 298 (15–1109) 658 (148–2328)
CD4 <200 cells/ml, n (%) 53/276 (19) 34/71 (48) 19/40 (48) 6/176 (3)
Weight, kg, mean (SD) 51.5 (9.1) 49.9 (9.1) 50.5 (10.4) 52.4 (8.9)
Dead at 12 months follow-up, n (%) 54 (15) 30 (32) 9 (16) 15 (7)
a Including the 19 dually infected.
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(range 400–5 702 830) and for v2.0 was 84 730 copies/ml (range
200–9 373 620); the difference was highly signiﬁcant at all time-
points (Table 3). HIV RNA was below the LLD in 10 patients using
v1.0 and 7 patients using v2.0.
Median p24 was 9.9 pg/ml (range 0.3–157.1). The LLDs for the
p24 antigen assay were 1.32, 1.43, 4.38, and 1.79 pg/ml for the four
runs. Seventy-two samples had p24 antigen <LLD (including the
samples from the seven patients with plasma HIV RNA < LLD). Due
to the variation in LLD, the numerical values were used in the
correlation analysis.
No signiﬁcant differences were found between the two vitamin
D arms: at baseline, the median HIV RNA among 53 vitamin D-
treated patients was 83 150 copies/ml and among the 40 HIV-1
patients in the placebo group, the median HIV RNA was 98 635
copies/ml (p = 0.27). At 8 months, median HIV RNA among 25
vitamin D-treated patients was 54 060 copies/ml and among 22
placebo-treated patients it was 68 500 copies/ml (p = 0.35). We
therefore chose to analyze the data together. Since v2.0 was found
to be superior, only HIV RNA analyzed with v2.0 is used in the
following.
No signiﬁcant changes in HIV RNA over time were found
(Table 2). Figure 1A also demonstrates few changes in HIV RNA
over time. Median p24 antigen values were unchanged (Table 2
and Figure 1B). CD4 counts were not available at 2 and 5 months of
treatment, and were unchanged at 8 months (Table 2). We found
that p24 correlated well with HIV RNA: Spearman’s R2 = 0.52,
p < 0.00001 (Figure 2). CD4 cell counts also correlated with p24
(R2 = 0.29, p = 0.01).
3.3. Mortality
Comparing the patients who died within 1 year of follow-up
with those who remained alive, we found that the baseline CD4Table 2
HIV RNA, p24 antigen, and CD4 cell count during tuberculosis treatment
Median HIV RNA v1.0 (copies/ml)a
Median HIV RNA v2.0 (copies/ml)b
p-Value for difference v1.0/v2.0c
Median p24 
Mean CD4 count in HIV-1-infected 
CD4 in HIV-uninfected patients with complete follow-up and available CD4 count 
Mean TBscore (range) 
a Samples with no HIV RNA found contributed with the cut-off value 399 copies/ml
b Samples with no HIV RNA found contributed with the cut-off value 199 copies/ml
c p = probability using linear regression.count was considerably lower in the patients who died (n = 42 with
available CD4 counts); mean CD4 count was 300 cells/ml compared
with 574 cells/ml in the group of survivors (p < 0.001). This was
entirely because of differences within the HIV-1-infected, where
the mean CD4 count was 362 cells/ml in those alive at 12 months
compared with 197 cells/ml in the patients who died within the
follow-up period (p = 0.01). No difference was found among the
HIV-uninfected, but few HIV-uninfected were dead at follow-up
(data not shown). Among the HIV-1-infected who were dead at
follow-up (n = 30), the mean HIV-RNA was signiﬁcantly higher
than in the surviving group (n = 63) (883 117 vs. 314 753 copies/
ml, p = 0.04), and baseline p24 was also signiﬁcantly higher in the
patients who were dead at follow-up (34.9 vs. 18.6, p = 0.01).
We assessed how the various markers of HIV infection at
baseline were associated with mortality (Figure 3). We found that a
CD4 count below 200 cells/ml was strongly associated with
mortality risk, and this cut-off point accurately predicted subse-
quent mortality (Figure 3A, log rank test p = 0.001). Also, among
the HIV-1-uninfected we noted that a low CD4 count predicted
mortality; a CD4 count below 400 cells/ml was associated with
increased mortality (Figure 3B, log rank test p = 0.046).
A high HIV RNA at baseline was also strongly associated with
mortality risk, but a threshold below which the mortality was
substantially reduced could not be identiﬁed as there was also a
considerable mortality among patients with low HIV RNA and even
among patients with HIV RNA below the LLD (Figure 3C, log rank
test p = 0.05). For Figure 3C, the 25th percentile, 1000 copies/ml,
and the 75th percentile, 100 000 copies/ml, were chosen (Table 3).
p24 was associated with mortality similarly to HIV RNA;
mortality was also seen in patients with very low levels of p24
antigen (Figure 3D, log rank test p = 0.04). For Figure 3D, the 25th
and 75th percentiles were also chosen as cut-offs.
Receiver operating characteristics (ROC) curve analysis under-
lined the predictive capacity for mortality of all three biomarkers,Inclusion (n) 2 months (n) 5 months (n) 8 months (n)
21 440 (93) 16 735 (72) 35 225 (62) 23 080 (47)
84 730 (93) 97 990 (72) 113 710 (62) 54 170 (47)
<0.001 <0.001 <0.001 <0.001
9.9 (93) 8.5 (72) 11.3 (62) 6.4 (47)
307 (71) 317 (38)
702 (92) 736 (92)
6.9 (2–11) (93) 2.6 (0–10) (72) 1.5 (0–9) (62) 1.2 (0–5) (47)
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Figure 1. (A) Box plot of HIV RNA levels during tuberculosis treatment (v2.0). (B)
Box plot of p24 antigen levels over time.
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Figure 2. Scatter plot of plasma p24 and plasma HIV RNA (v2.0).
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both HIV RNA and p24 were 0.66. The best cut-offs for mortality
risk identiﬁed from the curve (ﬁgure not shown) were 50 000
copies/ml for HIV RNA and 30 pg/ml for p24, respectively; these
cut-offs had a sensitivity of 50% and a speciﬁcity of 75% for
mortality risk.
3.4. Clinical severity of TB and HIV RNA
We found a correlation between a clinical severity index, the
Bandim TBscore, and HIV RNA (at baseline) (Spearman’s R2 = 0.23,
p = 0.02), indicating an association with high HIV RNA in
symptomatic patients. Several components of the TBscore are
signs and symptoms also present in severe HIV disease. Yet, the
clinical severity of TB decreased during TB treatment although HIV
RNA was unchanged (Table 2).B
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Table 3
Distribution of patients HIV RNA levels at TB treatment start with Roche COBAS
AmpliPrep/COBAS TaqMan HIV-1 Test v1.0 and v2.0
HIV RNA (copies/ml) Version 1.0
(number of patients)
Version 2.0
(number of patients)
<LLD 10 6
LLD–10 000 29 12
10 001–100 000 29 35
>100 000 25 40
LLD, lower limit of detection.
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Among HIV-infected patients not receiving ART we found stable
levels of HIV viremia expressed as HIV RNA and p24 antigen load,
from initiation of TB treatment and during 8 months of follow-up;
the CD4 cell count also remained stable.
As we found lower than anticipated HIV RNA values among
these HIV-untreated TB co-infected patients, we repeated HIV RNA
measurements with v2.0, which in addition to the gag primers also
has LTR primers, presumably securing detection of a broader range
of HIV types. However, we still found a number of patients with
HIV RNA <LLD using v2.0. A possible explanation could be that
some of the patients with undetectable HIV RNA were dually HIV-1
+ HIV-2 infected, and they may have been incorrectly diagnosed
with HIV-1 since the current testing regimen has been shown to
misclassify patients with HIV-2 single infection as HIV-1 + HIV-2
dual infection.20
The few studies investigating changes in HIV parameters during
TB treatment have shown differing results. Small studies from
various countries on the African continent have shown persistently
high viral loads and stable or decreasing CD4 cell counts after TB
treatment.6,7,20 Kizza et al.17 found a signiﬁcant, though clinically
probably not very important decline of 0.2 log10 copies/ml at
completion of TB treatment (month 6), and a viral load at month 12
not signiﬁcantly different from the baseline value. In a study from
South Africa, a cohort of HIV-infected patients developing TB had
higher HIV loads prior to TB diagnosis than CD4 matched control
patients, with no signiﬁcant change during follow-up. HIV-infected
patients from the same cohort developing bacterial pneumonia
had non-signiﬁcant higher viral loads than matched controls and
no change in viremia after resolution of the pneumonia episode.21
We found similar proﬁles for HIV RNA and p24 antigen. The p24
antigen levels during TB treatment have, to our knowledge, not
previously been investigated. Among the HIV-uninfected patients,
no changes in CD4 cell count in conjunction with TB treatment
were found. To our knowledge this has only previously been
described recently in Tanzania.14
In contrast to the current study and the studies mentioned
above,6,7,20 Dean et al.5 found signiﬁcant decreases in viral load and
signiﬁcant increases in CD4 cell counts within 12 months after
initiating TB treatment among co-infected patients, even in the
subgroup (n = 20) not receiving concomitant ART. The reason for
this discrepancy is not clear, but could be related to the setting, as
the latter study was performed in the developed world.
p24 correlated with HIV RNA with a correlation coefﬁcient of
0.52. In a study from Zimbabwe, we found a similar correlation
between the two viral load markers.10 In Guinea-Bissau the main
strain of HIV-1 is subtype A/G,22whereas subtype C is predominant
in Zimbabwe. This conﬁrms that the correlation does not depend
on subtype.23 In line with previous studies, we found that p24
antigen provided prognostic information.10,24
A major limitation of this study is the relatively small sample
size of patients with complete follow-up. The main reason for this
is that patients had died before follow-up, but still we found nomajor difference in levels of the markers when analyzing the entire
cohort compared with those with complete follow-up. Another
limitation is that our data originate from a trial where measure-
ment of viral markers was not the primary objective. However, we
found no difference in the primary outcome measures in the two
trial arms, hence all patients are included in the current analyses.
We had no reason to believe that the vitamin D intervention would
affect the levels of the markers in the current study, and we
therefore pooled the two trial arms.
In conclusion, we found no signiﬁcant changes in CD4, HIV RNA,
or p24 antigen levels during 8 months of TB treatment among TB/
HIV co-infected individuals not receiving ART. All three markers
showed predictive capacity for mortality risk but were unaffected
by a strong improvement in TB symptoms during anti-TB
treatment.
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